Profile data is unavailable for this security.
About the company
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
- Revenue in USD (TTM)10.06m
- Net income in USD-77.09m
- Incorporated2018
- Employees73.00
- LocationArbutus Biopharma Corp701 Veterans CircleWARMINSTER 18974United StatesUSA
- Phone+1 (267) 469-0914
- Fax+1 (604) 419-3201
- Websitehttps://www.arbutusbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 720.42m | 267.00 | 104.37 | -- | 78.13 | 1.80 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 740.67m | 58.00 | -- | 2.20 | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 740.94m | 266.00 | -- | -- | -- | 6.71 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Annexon Inc | 0.00 | -115.16m | 742.22m | 71.00 | -- | 2.05 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Savara Inc | 0.00 | -75.29m | 763.75m | 37.00 | -- | 6.30 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Replimune Group Inc | 0.00 | -220.01m | 767.25m | 331.00 | -- | 1.80 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 778.82m | 80.00 | -- | 3.43 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Arbutus Biopharma Corp | 10.06m | -77.09m | 781.56m | 73.00 | -- | 6.38 | -- | 77.68 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 787.25m | 107.00 | -- | 2.50 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Stoke Therapeutics Inc | 15.16m | -103.57m | 797.09m | 110.00 | -- | 3.26 | -- | 52.59 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| AbCellera Biologics Inc | 33.06m | -153.30m | 807.38m | 586.00 | -- | 0.7267 | -- | 24.43 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Arrivent Biopharma Inc | 0.00 | -74.89m | 812.78m | 40.00 | -- | 2.73 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Dianthus Therapeutics Inc | 4.12m | -56.68m | 824.86m | 53.00 | -- | 2.30 | -- | 200.31 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Erasca Inc | 0.00 | -158.28m | 839.04m | 126.00 | -- | 1.80 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Arbutus Biopharma Corp's reporting currency: US Dollar USD
39.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 30 Jun 2024 | 19.41m | 10.28% |
| Whitefort Capital Management, LPas of 30 Jun 2024 | 12.87m | 6.82% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 10.58m | 5.60% |
| Two Seas Capital LPas of 30 Jun 2024 | 8.57m | 4.54% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 6.77m | 3.59% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.31m | 1.76% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 3.29m | 1.74% |
| Adage Capital Management LPas of 30 Jun 2024 | 3.00m | 1.59% |
| FourWorld Capital Management LLCas of 30 Jun 2024 | 2.97m | 1.58% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.93m | 1.55% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
